Results 21 to 30 of about 267,421 (217)

AM-251, A Cannabinoid Antagonist, Modifies the Dynamics of Sleep–Wake Cycles in Rats

Frontiers in Pharmacology, 2019
Study Objectives: (a) To describe the microarchitecture of wakefulness and sleep following administrations of 5- and 10-mg/kg AM-251 in rats. (b) To develop a new statistical method to follow bout-to-bout dynamics.Method: Wistar rats (n = 6) had been ...
Emese Bogáthy, Noémi Papp, Szilvia Vas, Szilvia Vas, Szilvia Vas, György Bagdy, György Bagdy, György Bagdy, György Bagdy, László Tóthfalusi   +9 more
doaj   +1 more source

A Bayesian dose-response meta-analysis model: simulation study and application [PDF]

Vol 30, Issue 5, 2021, 2020
Dose-response models express the effect of different dose or exposure levels on a specific outcome. In meta-analysis, where aggregated-level data is available, dose-response evidence is synthesized using either one-stage or two-stage models in a frequentist setting. We propose a hierarchical dose-response model implemented in a Bayesian framework.
arxiv   +1 more source

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

American Journal of Psychiatry, 2019
OBJECTIVE About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective ...
V. Popova, E. Daly, M. Trivedi, K. Cooper, R. Lane, P. Lim, Christine Mazzucco, D. Hough, M. Thase, R. Shelton, P. Molero, E. Vieta, M. Bajbouj, H. Manji, W. Drevets, Jaskaran Singh   +15 more
semanticscholar   +1 more source

Neural Predictors of the Antidepressant Placebo Response

Pharmaceuticals, 2019
The antidepressant placebo response remains a barrier to the development of novel therapies for depression, despite decades of efforts to identify and methodologically address its clinical correlates.
Danielle Rette, Erin McDonald, Dan V. Iosifescu, Katherine A. Collins   +3 more
doaj   +1 more source

Designing AI for Trust and Collaboration in Time-Constrained Medical Decisions: A Sociotechnical Lens [PDF]

, 2021
Major depressive disorder is a debilitating disease affecting 264 million people worldwide. While many antidepressant medications are available, few clinical guidelines support choosing among them. Decision support tools (DSTs) embodying machine learning models may help improve the treatment selection process, but often fail in clinical practice due to
arxiv   +1 more source

Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation

Science, 2019
Why is ketamine an antidepressant? A better understanding of the mechanisms underlying the action of antidepressants is urgently needed. Moda-Sava et al.
R. N. Moda-Sava, Mitchell H. Murdock, P. Parekh, R. Fetcho, Ben S. Huang, T. N. Huynh, Jonathan Witztum, D. Shaver, D. Rosenthal, E. Alway, Katherine Lopez, Y. Meng, L. Nellissen, L. Grosenick, L. Grosenick, T. Milner, K. Deisseroth, H. Bito, H. Kasai, C. Liston   +19 more
semanticscholar   +1 more source

Chronic Fluoxetine Treatment Induces Maturation-Compatible Changes in the Dendritic Arbor and in Synaptic Responses in the Auditory Cortex

Frontiers in Pharmacology, 2019
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat mood and anxiety disorders. Chronic treatment with this antidepressant drug is thought to favor functional recovery by promoting structural and molecular changes in several ...
Estibaliz Ampuero, Mauricio Cerda, Steffen Härtel, Steffen Härtel, Francisco Javier Rubio, Solange Massa, Paula Cubillos, Lorena Abarzúa-Catalán, Rodrigo Sandoval, Albert M. Galaburda, Ursula Wyneken   +10 more
doaj   +1 more source

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA psychiatry, 2019
Importance Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.
E. Daly, M. Trivedi, A. Janik, Honglan Li, Yun Zhang, Xiang Li, R. Lane, P. Lim, A. Duca, D. Hough, M. Thase, J. Zajecka, A. Winokur, I. Divacka, A. Fagiolini, W. Cubała, I. Bitter, P. Blier, R. Shelton, P. Molero, H. Manji, W. Drevets, Jaskaran Singh   +22 more
semanticscholar   +1 more source

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Psychological Medicine, 2018
Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression.
Fernanda Palhano-Fontes, Dayanna Barreto, H. Onias, K. Andrade, Morgana M. Novaes, J. Pessoa, S. Mota-Rolim, F. Osório, R. Sanches, R. G. dos Santos, L. F. Tófoli, Gabriela de Oliveira Silveira, M. Yonamine, J. Riba, F. Santos, Antonio A Silva-Junior, J. Alchieri, N. Galvão-Coelho, B. Lobão-Soares, J. Hallak, Emerson Arcoverde, J. P. Maia-de-Oliveira, D. Araujo   +22 more
semanticscholar   +1 more source

Antidepressant use and spatial social capital [PDF]

arXiv, 2023
Social capital may help individuals maintain their mental health. Most empirical work based on small-scale surveys finds that bonding social capital and cohesive social networks are critical for mental well-being, while bridging social capital and diverse networks are considered less important.
arxiv